Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Shibo Jiang
Christopher Hillyer
Lanying Du
Open AccessPublished:April 02, 2020DOI:https://doi.org/10.1016/j.it.2020.03.007
Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.